Chronic Nonbacterial Osteomyelitis, Hidradenitis Suppurativa, and SAPHO Syndrome
Main Article Content
Keywords
hidradenitis suppurativa, SAPHO, chronic nonbacterial osteomyelitis, case report
Abstract
Introduction: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome may represent one side of a spectrum of disease that also includes chronic nonbacterial osteomyelitis.
Case: A 23-year-old male with bone pain in the anterior chest, shoulder, clavicles, left elbow, and left ankle presented to rheumatology clinic after multiple evaluations for infectious osteomyelitis. Imaging and deep bone biopsies of affected areas were consistent with chronic osteomyelitis, with labs notable for elevated erythrocyte sedimentation rate, C-reactive protein, and positivity for HLA-B27. A full skin exam was consistent with hidradenitis suppurativa, and he was started on infliximab and methotrexate with improvement in both his osteoarticular and skin symptoms.
Conclusions: Patients presenting with features of follicular occlusion or neutrophilic dermatoses in conjunction with bone pain should be evaluated for SAPHO/CNO. In patients with SAPHO/CNO with vertebral involvement, bisphosphonates in addition to anti-inflammatory medications (such as methotrexate and TNF-inhibitors) can be effective.
References
2. Hedrich CM, Morbach H, Reiser C, Girschick HJ. New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO. Curr Rheumatol Rep. Jul 23 2020;22(9):52. doi:10.1007/s11926-020-00928-1
3. Rukavina I. SAPHO syndrome: a review. J Child Orthop. Feb 2015;9(1):19-27. doi:10.1007/s11832-014-0627-7
4. Vekic DA, Woods J, Lin P, Cains GD. SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol. Jan 2018;57(1):10-18. doi:10.1111/ijd.13740
5. Fania L, Moro F, Clemente A, et al. Successful treatment of Sapho syndrome and hidradenitis suppurativa: A therapeutic challenge. Dermatol Ther. May 2020;33(3):e13453. doi:10.1111/dth.13453
6. Crowley EL, O'Toole A, Gooderham MJ. Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections. SAGE Open Med Case Rep. 2018;6:2050313x18778723. doi:10.1177/2050313x18778723
7. Hattori K, Takahashi N, Suzuki M, Kojima T, Imagama S. A Case of Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO) Syndrome with Isolated Lesions of the Thoracic Spine. Mod Rheumatol Case Rep. Mar 29 2022;doi:10.1093/mrcr/rxac030
8. Gasparic J, Theut Riis P, Jemec GB. Recognizing syndromic hidradenitis suppurativa: a review of the literature. J Eur Acad Dermatol Venereol. Nov 2017;31(11):1809-1816. doi:10.1111/jdv.14464
9. Briede K, Valiukeviciene S, Kucinskiene V, Gollnick HPM. Biologic Therapy for Hidradenitis Suppurativa Plus Conglobate Acne Associated with SAPHO Syndrome: A Case Report. Acta Derm Venereol. Nov 4 2020;100(18):adv00311. doi:10.2340/00015555-3672
10. Genovese G, Caorsi R, Moltrasio C, Marzano AV. Successful treatment of co-existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexate. J Eur Acad Dermatol Venereol. Oct 2019;33 Suppl 6:40-41. doi:10.1111/jdv.15849
11. De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185-7.
12. Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis SN. Biologics in SAPHO syndrome: A systematic review. Semin Arthritis Rheum. Feb 2019;48(4):618-625. doi:10.1016/j.semarthrit.2018.04.003
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.